$GFLT
GenFlat Holdings, Inc.

2024 Q2 Form 10-Q Financial Statement

#000165495424006435 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q2
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $28.84K
YoY Change -55.91%
% of Gross Profit
Research & Development $0.00
YoY Change -100.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $200.0K $28.84K
YoY Change 348.11% -55.91%
Operating Profit -$200.0K -$28.84K
YoY Change 14.87% -54.6%
Interest Expense $440.00 $2.427K
YoY Change -113.66% -63.99%
% of Operating Profit
Other Income/Expense, Net $13.00 -$2.427K
YoY Change -101.71% -122.96%
Pretax Income -$31.27K
YoY Change -40.96%
Income Tax
% Of Pretax Income
Net Earnings -$200.0K -$31.27K
YoY Change 317.93% -40.96%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 1.054B shares 1.054B shares 21.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.07K
YoY Change -12.87%
Cash & Equivalents $38.97K $142.6K $22.07K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $1.661M $1.590M $0.00
Prepaid Expenses $0.00 $0.00 $477.0K
Receivables
Other Receivables
Total Short-Term Assets $44.21K $1.733M $120.8K
YoY Change -63.4% 1331.23% -22.93%
LONG-TERM ASSETS
Property, Plant & Equipment $1.208K $1.409K $2.214K
YoY Change -45.44%
Goodwill
YoY Change
Intangibles $186.3K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.751M $102.3K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $44.21K $1.733M $120.8K
Total Long-Term Assets $1.751M $102.3K $0.00
Total Assets $1.795M $1.835M $120.8K
YoY Change 1386.61% 1415.72% -22.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $107.9K $109.0K $92.22K
YoY Change 16.98% 19.54% -17.53%
Accrued Expenses $9.877K $9.877K $5.659K
YoY Change 74.54% 193.26% 95.75%
Deferred Revenue
YoY Change
Short-Term Debt $101.4K
YoY Change -59.42%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $226.8K $69.08K $199.3K
YoY Change 13.81% -61.57% -45.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $226.8K $69.08K $199.3K
Total Long-Term Liabilities $0.00
Total Liabilities $277.3K $119.6K $199.3K
YoY Change 39.14% -33.48% -45.35%
SHAREHOLDERS EQUITY
Retained Earnings -$3.150M -$2.761M -$3.498M
YoY Change -9.93% -20.35% 4.32%
Common Stock $10.55K $1.054M $21.30K
YoY Change -50.49% 4848.36% 2.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.476M $1.664M -$78.55K
YoY Change
Total Liabilities & Shareholders Equity $1.795M $1.835M $120.8K
YoY Change 1386.61% 1415.72% -22.93%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q2
OPERATING ACTIVITIES
Net Income -$200.0K -$31.27K
YoY Change 317.93% -40.96%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$290.00
YoY Change -99.14%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $8.170K
YoY Change 0.0%
Cash From Investing Activities $8.171K
YoY Change -0.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -$290.00
Cash From Investing Activities $8.171K
Cash From Financing Activities $0.00
Net Change In Cash $7.881K
YoY Change -1252.19%
FREE CASH FLOW
Cash From Operating Activities -$290.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Interest Expense
InterestExpense
805 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001796949
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1020519491 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1054150003 shares
CY2021Q1 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
125000 usd
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1054150000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1054150000 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56214
dei Entity Address Address Line1
EntityAddressAddressLine1
1983 N Berra Blvd
dei Entity Registrant Name
EntityRegistrantName
Healthcare Business Resources Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3639946
dei Entity Address City Or Town
EntityAddressCityOrTown
Tooele
dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84074
dei City Area Code
CityAreaCode
435
dei Local Phone Number
LocalPhoneNumber
830-6979
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1054150003 shares
CY2024Q1 us-gaap Inventory Net
InventoryNet
1590000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
0 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
125000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-125609 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
125280 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
199991 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48816 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
199991 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
174096 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-199991 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-174096 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
440 usd
CY2024Q1 us-gaap Other Income
OtherIncome
453 usd
CY2023Q1 us-gaap Other Income
OtherIncome
45 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-760 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-199978 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-174856 usd
CY2024Q1 hbr Net Loss Attributable To Noncontrolling Interest
NetLossAttributableToNoncontrollingInterest
8033 usd
CY2023Q1 hbr Net Loss Attributable To Noncontrolling Interest
NetLossAttributableToNoncontrollingInterest
0 usd
CY2024Q1 hbr Net Loss Attributable To Healthcare Business Resources Inc
NetLossAttributableToHealthcareBusinessResourcesInc
-191945 usd
CY2023Q1 hbr Net Loss Attributable To Healthcare Business Resources Inc
NetLossAttributableToHealthcareBusinessResourcesInc
-174856 usd
hbr Net Loss Attributable To Healthcare Business Resources Inc
NetLossAttributableToHealthcareBusinessResourcesInc
-897567 usd
hbr Net Loss Attributable To Healthcare Business Resources Inc
NetLossAttributableToHealthcareBusinessResourcesInc
-432019 usd
CY2024Q1 hbr Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.00
CY2023Q1 hbr Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.00
CY2024Q1 hbr Loss Per Share Basic And Diluted Attributable To Noncontrolling Interest
LossPerShareBasicAndDilutedAttributableToNoncontrollingInterest
-0.00
CY2023Q1 hbr Loss Per Share Basic And Diluted Attributable To Noncontrolling Interest
LossPerShareBasicAndDilutedAttributableToNoncontrollingInterest
-0.00
CY2024Q1 hbr Weighted Average Shares Outstanding Basic And Diluted
WeightedAverageSharesOutstandingBasicAndDiluted
1054150003 shares
CY2023Q1 hbr Weighted Average Shares Outstanding Basic And Diluted
WeightedAverageSharesOutstandingBasicAndDiluted
993399680 shares
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
481816 usd
CY2022Q3 hbr Recapitalization Amount
RecapitalizationAmount
0 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-60358 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
421458 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-196805 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
224653 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-174856 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
49797 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
780189 usd
CY2023Q3 hbr Common Stock Sold For Cash Amount
CommonStockSoldForCashAmount
200000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
854580 usd
CY2023Q4 hbr Common Stock Sold For Cash Amount
CommonStockSoldForCashAmount
1889300 usd
CY2023Q4 hbr Recapitalization Amount
RecapitalizationAmount
-247295 usd
CY2023Q4 hbr Reclassification Of Noncontrolling Interest Amount
ReclassificationOfNoncontrollingInterestAmount
0 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-581255 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1915330 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-199978 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1715352 usd
us-gaap Profit Loss
ProfitLoss
906842 usd
us-gaap Profit Loss
ProfitLoss
432019 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
97879 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
10008 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
9388 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-477000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1590000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-100178 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2420 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-10308 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-9538 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2022441 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-429749 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
74500 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
128466 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2089300 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1886334 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-136107 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-429749 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
278756 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
434831 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
142649 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5082 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q4 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.971 pure
CY2024Q1 hbr Agreement Of Termination
AgreementOfTermination
the 1,400,000 common stock warrants with an exercise price of $0.50 per share were cancelled, and 1,000,000 shares of common stock
CY2024Q1 us-gaap Inventory Net
InventoryNet
1590000 usd
us-gaap Description Of Lessor Leasing Arrangements Operating Leases
DescriptionOfLessorLeasingArrangementsOperatingLeases
The Company maintains an operating lease for its office space
hbr Finite Lived Intangible Assets Remainings Amortization Period
FiniteLivedIntangibleAssetsRemainingsAmortizationPeriod
P10M
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
11652 usd
CY2024Q1 us-gaap Lease Deposit Liability
LeaseDepositLiability
11468 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
8011 usd
CY2023Q2 us-gaap Lease Deposit Liability
LeaseDepositLiability
8127 usd
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
10500 usd
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
10650 usd
hbr Remainingestimated Life
RemainingestimatedLife
P0Y9M29D
CY2022Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
100000 usd
hbr Increased Decreased In Convetible Note Amount
IncreasedDecreasedInConvetibleNoteAmount
150000 usd
hbr Amendment Description Related To Issue Of Shares
AmendmentDescriptionRelatedToIssueOfShares
it shall have authority to issue from 200,000,000 shares to 2,500,000,000 shares
CY2022Q2 us-gaap Debt Instrument Description
DebtInstrumentDescription
The Company paid $20,000 in cash to the consultant and agreed to pay an additional $20,000 upon filing of a prospectus, $25,000 upon effectiveness of such prospectus, and $25,000 upon public listing of the Company’s shares of common stock
CY2024Q1 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Percentage
BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
0.10 pure
us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
1000000 shares
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
534825 shares
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2139300 usd
CY2023 hbr Cash Returned To An Investor
CashReturnedToAnInvestor
50000 usd
CY2023Q4 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Percentage
BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
0.0278 pure
CY2023Q4 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.971 pure
CY2023Q4 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Percentage
BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
0.9722 pure
CY2023Q4 us-gaap Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares
StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares
1043847000 shares
CY2023Q4 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
11000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1054150000 shares
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
108953 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9877 usd
CY2024Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
128466 usd
CY2024Q1 hbr Liabilities Current Assumed
LiabilitiesCurrentAssumed
247296 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1580000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.57
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
810000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.64
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
770000 shares
CY2024Q1 hbr Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice Ending Balance
SharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepriceEndingBalance
0.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
764000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M
CY2024Q1 hbr Advances From Related Party
AdvancesFromRelatedParty
8731 usd
hbr Consultingfees Services
ConsultingfeesServices
15000 usd
hbr Annual Salary Received
AnnualSalaryReceived
150000 usd
hbr Gross Transaction Fee
GrossTransactionFee
70000 usd

Files In Submission

Name View Source Status
0001654954-24-006435-index-headers.html Edgar Link pending
0001654954-24-006435-index.html Edgar Link pending
0001654954-24-006435.txt Edgar Link pending
0001654954-24-006435-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hbr-20240331.xsd Edgar Link pending
hbr_10q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hbr-20240331_cal.xml Edgar Link unprocessable
hbr-20240331_def.xml Edgar Link unprocessable
hbr-20240331_lab.xml Edgar Link unprocessable
hbr_ex102.htm Edgar Link pending
hbr_ex311.htm Edgar Link pending
hbr_ex312.htm Edgar Link pending
hbr_10q_htm.xml Edgar Link completed
hbr_ex321.htm Edgar Link pending
hbr_ex322.htm Edgar Link pending
hbr_ex33.htm Edgar Link pending
hbr_ex33img1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hbr-20240331_pre.xml Edgar Link unprocessable